Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karen M Alsante

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of Pharmaceutical Sciences|February 6, 2010
A critical assessment of the ICH guideline on photostability testing of new drug substances and products (Q1B): Recommendation for revisionSteven W Baertschi, Karen M Alsante, Hanne H Tønnesen
Advanced Drug Delivery Reviews|December 26, 2006
The role of degradant profiling in active pharmaceutical ingredients and drug productsKaren M Alsante, Akemi Ando, Roland Brown, et al.
Pharmaceutical Development and Technology|February 21, 2002
Stabilization of pharmaceuticals to oxidative degradationKenneth C Waterman, Roger C Adami, Karen M Alsante, et al.
Journal of Pharmaceutical and Biomedical Analysis|October 22, 2004
Identification of low-level degradants from low dose tabletsAndrew Blanchard, Carlos Lee, Beverly Nickerson, et al.
Molecular Pharmaceutics|November 4, 2014
In silico prediction of pharmaceutical degradation pathways: a benchmarking studyMark H Kleinman, Steven W Baertschi, Karen M Alsante, et al.
AAPS Pharmscitech|December 24, 2013
Recent trends in product development and regulatory issues on impurities in active pharmaceutical ingredient (API) and drug products. Part 2: Safety considerations of impurities in pharmaceutical products and surveying the impurity landscapeKaren M Alsante, Kim C Huynh-Ba, Steven W Baertschi, et al.
Pharmaceutical Development and Technology|June 18, 2002
Hydrolysis in pharmaceutical formulationsKenneth C Waterman, Roger C Adami, Karen M Alsante, et al.
AAPS Pharmscitech|November 28, 2013
Recent trends in product development and regulatory issues on impurities in active pharmaceutical ingredient (API) and drug products. Part 1: Predicting degradation related impurities and impurity considerations for pharmaceutical dosage formsKaren M Alsante, Kim Huynh-Ba, Steven W Baertschi, et al.
Journal of Pharmaceutical Sciences|August 6, 2004
Pharmaceutical impurity identification: a case study using a multidisciplinary approachKaren M Alsante, Peter Boutros, Michel A Couturier, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Pharmaceutical Sciences|February 6, 2010
A critical assessment of the ICH guideline on photostability testing of new drug substances and products (Q1B): Recommendation for revisionSteven W Baertschi, Karen M Alsante, Hanne H Tønnesen
Advanced Drug Delivery Reviews|December 26, 2006
The role of degradant profiling in active pharmaceutical ingredients and drug productsKaren M Alsante, Akemi Ando, Roland Brown, et al.
Pharmaceutical Development and Technology|February 21, 2002
Stabilization of pharmaceuticals to oxidative degradationKenneth C Waterman, Roger C Adami, Karen M Alsante, et al.
Journal of Pharmaceutical and Biomedical Analysis|October 22, 2004
Identification of low-level degradants from low dose tabletsAndrew Blanchard, Carlos Lee, Beverly Nickerson, et al.
Molecular Pharmaceutics|November 4, 2014
In silico prediction of pharmaceutical degradation pathways: a benchmarking studyMark H Kleinman, Steven W Baertschi, Karen M Alsante, et al.
AAPS Pharmscitech|December 24, 2013
Recent trends in product development and regulatory issues on impurities in active pharmaceutical ingredient (API) and drug products. Part 2: Safety considerations of impurities in pharmaceutical products and surveying the impurity landscapeKaren M Alsante, Kim C Huynh-Ba, Steven W Baertschi, et al.
Pharmaceutical Development and Technology|June 18, 2002
Hydrolysis in pharmaceutical formulationsKenneth C Waterman, Roger C Adami, Karen M Alsante, et al.
AAPS Pharmscitech|November 28, 2013
Recent trends in product development and regulatory issues on impurities in active pharmaceutical ingredient (API) and drug products. Part 1: Predicting degradation related impurities and impurity considerations for pharmaceutical dosage formsKaren M Alsante, Kim Huynh-Ba, Steven W Baertschi, et al.
Journal of Pharmaceutical Sciences|August 6, 2004
Pharmaceutical impurity identification: a case study using a multidisciplinary approachKaren M Alsante, Peter Boutros, Michel A Couturier, et al.
Pageof 1